Compare GSAT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSAT | BMRN |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.3B |
| IPO Year | 2006 | 1999 |
| Metric | GSAT | BMRN |
|---|---|---|
| Price | $83.13 | $55.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 27 |
| Target Price | $90.00 | ★ $91.62 |
| AVG Volume (30 Days) | 558.6K | ★ 2.1M |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.58 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $112,660,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $8.42 | $21.29 |
| Revenue Next Year | $20.04 | $14.48 |
| P/E Ratio | ★ N/A | $71.95 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $40.50 | $49.26 |
| 52 Week High | $84.85 | $70.98 |
| Indicator | GSAT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 26.85 |
| Support Level | $80.87 | $55.28 |
| Resistance Level | $84.77 | $57.95 |
| Average True Range (ATR) | 0.57 | 1.41 |
| MACD | 0.03 | -0.53 |
| Stochastic Oscillator | 56.31 | 14.27 |
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services, including voice and data communications services to retail, business, and governmental customers, as well as wholesale satellite capacity services. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is the owner of satellite assets. It has one reportable segment: the MSS business. The company generates the vast majority of its revenue within the United States.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.